VELCADE Trademark

Trademark Overview

On Friday, April 19, 2002, a trademark application was filed for VELCADE with the United States Patent and Trademark Office. The USPTO has given the VELCADE trademark a serial number of 76397478. The federal status of this trademark filing is REGISTERED AND RENEWED as of Monday, April 22, 2024. This trademark is owned by Millennium Pharmaceuticals, Inc.. The VELCADE trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceuticals, namely, proteasome inhibitors; and pharmaceutical preparations for treatment of myelomas, leukemias, and cancers; pharmaceutical preparations for use in chemotherapy
velcade

General Information

Serial Number76397478
Word MarkVELCADE
Filing DateFriday, April 19, 2002
Status800 - REGISTERED AND RENEWED
Status DateMonday, April 22, 2024
Registration Number2795745
Registration DateTuesday, December 16, 2003
Mark Drawing1 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 29, 2002

Trademark Statements

Goods and Servicespharmaceuticals, namely, proteasome inhibitors; and pharmaceutical preparations for treatment of myelomas, leukemias, and cancers; pharmaceutical preparations for use in chemotherapy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 30, 2002
Primary Code005
First Use Anywhere DateMonday, May 19, 2003
First Use In Commerce DateMonday, May 19, 2003

Trademark Owner History

Party NameMillennium Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameMillennium Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameMillennium Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Wednesday, October 9, 2002NOTICE OF PUBLICATION
Friday, August 9, 2002ASSIGNED TO EXAMINER
Monday, August 12, 2002APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 29, 2002PUBLISHED FOR OPPOSITION
Tuesday, January 21, 2003NOA MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 21, 2003USE AMENDMENT FILED
Wednesday, July 23, 2003PAPER RECEIVED
Tuesday, September 16, 2003STATEMENT OF USE PROCESSING COMPLETE
Monday, September 29, 2003CASE FILE IN TICRS
Tuesday, September 30, 2003ASSIGNED TO EXAMINER
Sunday, October 19, 2003ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, December 16, 2003REGISTERED-PRINCIPAL REGISTER
Monday, November 29, 2004TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, November 29, 2004TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, March 20, 2009TEAS SECTION 8 & 15 RECEIVED
Monday, March 23, 2009ASSIGNED TO PARALEGAL
Wednesday, March 25, 2009REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Friday, May 10, 2013TEAS SECTION 8 & 9 RECEIVED
Thursday, June 6, 2013CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, June 6, 2013REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Thursday, June 6, 2013REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Thursday, June 6, 2013NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - MAILED
Tuesday, January 31, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 5, 2017REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
Friday, December 15, 2023TEAS SECTION 8 & 9 RECEIVED
Friday, April 19, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, April 22, 2024REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
Monday, April 22, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Monday, April 22, 2024REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

Related Keywords

velcade pharmaceutical preparations leukemias cancers chemotherapy myelomas treatment inhibitors namely pharmaceuticals